{"name":"Zydus Lifesciences","slug":"zydus-lifesciences","ticker":"ZYDUSLIFE.NS","exchange":"NSE","domain":"zyduslife.com","description":"Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopa","hq":"Ahmedabad, India","founded":0,"employees":"27917","ceo":"","sector":"Generics / Vaccines / Specialty","stockPrice":991.7,"stockChange":52.45,"stockChangePercent":5.58,"marketCap":"$10.4B","metrics":{"revenue":3200000000,"revenueGrowth":30.3,"grossMargin":72.4,"rdSpend":0,"netIncome":515743671.9412736,"cash":738201444.8455681,"dividendYield":1.17,"peRatio":20.2,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Januvia","genericName":"SITAGLIPTIN","slug":"sitagliptin","revenue":3200000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2006-01-01","label":"Januvia first approved","drug":"Januvia","drugSlug":"sitagliptin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":3200000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Januvia","genericName":"SITAGLIPTIN","slug":"sitagliptin","indication":"Diabetes mellitus type 2","status":"marketed","revenue":3200000000}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Pertuzumab (Perjeta®)","genericName":"Pertuzumab (Perjeta®)","slug":"pertuzumab-perjeta","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"Pertuzumab (ZRC-3277)","genericName":"Pertuzumab (ZRC-3277)","slug":"pertuzumab-zrc-3277","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Desidustat Oral Tablet","genericName":"Desidustat Oral Tablet","slug":"desidustat-oral-tablet","indication":"Anemia in chronic kidney disease patients not on dialysis","status":"phase_3"}]}],"pipeline":[{"name":"Januvia","genericName":"SITAGLIPTIN","slug":"sitagliptin","phase":"marketed","mechanism":"Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Desidustat Oral Tablet","genericName":"Desidustat Oral Tablet","slug":"desidustat-oral-tablet","phase":"phase_3","mechanism":"Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production.","indications":["Anemia in chronic kidney disease patients not on dialysis","Anemia in dialysis-dependent chronic kidney disease patients"],"catalyst":""},{"name":"Pertuzumab (Perjeta®)","genericName":"Pertuzumab (Perjeta®)","slug":"pertuzumab-perjeta","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"Pertuzumab (ZRC-3277)","genericName":"Pertuzumab (ZRC-3277)","slug":"pertuzumab-zrc-3277","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive gastric or gastroesophageal junction cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":2357503268.175,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":2357503268.175},{"period":"2024-03-31","value":1986517485.5625002},{"period":"2023-03-31","value":1762639372.1750002},{"period":"2022-03-31","value":1548525966.3500001}],"grossProfit":1661295284.275,"grossProfitHistory":[{"period":"2025-03-31","value":1661295284.275},{"period":"2024-03-31","value":1307645773.9125001},{"period":"2023-03-31","value":1077658191.0875},{"period":"2022-03-31","value":940826962.7625}],"rdSpend":19780060.025000002,"rdSpendHistory":[{"period":"2025-03-31","value":19780060.025000002},{"period":"2024-03-31","value":16271031.425},{"period":"2023-03-31","value":14182323.925},{"period":"2022-03-31","value":11968293.975000001}],"sgaSpend":315467937.26250005,"operatingIncome":624450437.7375001,"operatingIncomeHistory":[{"period":"2025-03-31","value":624450437.7375001},{"period":"2024-03-31","value":474053054.20000005},{"period":"2023-03-31","value":297933237.8},{"period":"2022-03-31","value":258383561.28750002}],"netIncome":472622289.56250006,"netIncomeHistory":[{"period":"2025-03-31","value":472622289.56250006},{"period":"2024-03-31","value":403068329.8125},{"period":"2023-03-31","value":204724665.6125},{"period":"2022-03-31","value":468632858.2375}],"eps":44.97,"epsHistory":[{"period":"2025-03-31","value":44.97},{"period":"2024-03-31","value":38.14},{"period":"2023-03-31","value":19.3},{"period":"2022-03-31","value":43.83}],"cash":86347168.05000001,"cashHistory":[{"period":"2025-03-31","value":86347168.05000001},{"period":"2024-03-31","value":43131809.875},{"period":"2023-03-31","value":50943575.925000004},{"period":"2022-03-31","value":68697589.67500001}],"totalAssets":3885173490.1375003,"totalLiabilities":1132424101.7375002,"totalDebt":335571746.95000005,"equity":2501550980.9125004,"operatingCashflow":707727205.7625,"operatingCashflowHistory":[{"period":"2025-03-31","value":707727205.7625},{"period":"2024-03-31","value":333806789.1125},{"period":"2023-03-31","value":280805836.3},{"period":"2022-03-31","value":219784246.68750003}],"capex":-178856023.22500002,"capexHistory":[{"period":"2025-03-31","value":-178856023.22500002},{"period":"2024-03-31","value":-94681110.97500001},{"period":"2023-03-31","value":-107662428.0875},{"period":"2022-03-31","value":-125593981.97500001}],"freeCashflow":528871182.5375,"dividendsPaid":-31591700.937500004,"buybacks":0,"employees":27917,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":154908991.7375,"ebitda":192463952.5875,"period":"2025-12-31","revenue":708113616.6500001,"epsBasic":10.36,"netIncome":108832104.28750001,"rdExpense":null,"epsDiluted":10.36,"grossProfit":516338937.5375,"operatingIncome":134972278.65},{"sga":null,"ebit":209424257.4875,"ebitda":234290320.275,"period":"2025-06-30","revenue":675383570.125,"epsBasic":14.58,"netIncome":153185808.05,"rdExpense":null,"epsDiluted":14.58,"grossProfit":488496466.56250006,"operatingIncome":187283957.9875},{"sga":null,"ebit":175054575.57500002,"ebitda":199899751.28750002,"period":"2025-03-31","revenue":656919395.825,"epsBasic":null,"netIncome":122283380.5875,"rdExpense":null,"epsDiluted":null,"grossProfit":445385543.76250005,"operatingIncome":201246967.625},{"sga":null,"ebit":127003859.53750001,"ebitda":150919560.41250002,"period":"2024-12-31","revenue":535074643.81250006,"epsBasic":10.17,"netIncome":106889606.31250001,"rdExpense":null,"epsDiluted":10.17,"grossProfit":369711671.0375,"operatingIncome":101928926},{"sga":null,"ebit":135348246,"ebitda":159744349.60000002,"period":"2024-09-30","revenue":534040733.6,"epsBasic":9.06,"netIncome":95161513.7,"rdExpense":null,"epsDiluted":9.06,"grossProfit":380374522.82500005,"operatingIncome":123484387.4}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":991.7,"previousClose":939.25,"fiftyTwoWeekHigh":1059.05,"fiftyTwoWeekLow":835.5,"fiftyTwoWeekRange":"835.5 - 1059.05","fiftyDayAverage":908.4,"twoHundredDayAverage":939.58,"beta":0.32,"enterpriseValue":10426152309.886158,"forwardPE":23.7,"priceToBook":3.94,"priceToSales":3.82,"enterpriseToRevenue":3.83,"enterpriseToEbitda":13.72,"pegRatio":0,"ebitda":760036313.1491328,"ebitdaMargin":27.9,"freeCashflow":0,"operatingCashflow":0,"totalDebt":1006349684.2865665,"debtToEquity":34.3,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":29,"targetMeanPrice":985.41,"targetHighPrice":1140,"targetLowPrice":800,"dividendRate":11,"payoutRatio":0.22,"fiveYearAvgDividendYield":0.83,"exDividendDate":1753401600,"insiderHeldPercent":75.2,"institutionHeldPercent":13.9,"sharesOutstanding":1006233990,"floatShares":249470290,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":49.03,"epsForward":41.81,"revenuePerShare":259.26,"bookValue":251.49,"officers":[{"age":46,"name":"Dr. Sharvil Pankajbhai Patel","title":"MD & Executive Director"},{"age":null,"name":"Mr. Punit  Patel","title":"President & CEO of America"},{"age":54,"name":"Mr. Tushar Dhansukh Shroff","title":"President of Finance & CFO"},{"age":null,"name":"Mr. Arvind  Bothra","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Dhaval Narendra Soni","title":"Company Secretary & Compliance Officer"},{"age":64,"name":"Mr. Nitinkumar Dalsukhray Parekh","title":"President of Special Projects"},{"age":51,"name":"Mr. Vikram  Shukla","title":"President of Parenteral Operations"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://zyduslife.com","phone":"91 79 4804 0000"}}